白细胞介素-35：一种用于自身免疫性疾病的潜在治疗剂。
Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases.
作者信息
Guan Shi-Yang, Leng Rui-Xue, Khan Muhammad Imran, Qureshi Humera, Li Xiang-Pei, Ye Dong-Qing, Pan Hai-Feng
机构信息
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, 230032, PR China.
Anhui Provincial Laboratory of Population Health and Major Disease Screening and Diagnosis, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, China.
出版信息
Inflammation. 2017 Feb;40(1):303-310. doi: 10.1007/s10753-016-0453-9.
Autoimmune diseases contain a large number of pathologies characterized by various factors that contribute to a breakdown in self-tolerance. Cytokine-mediated immunity plays an essential role in the pathogenesis of varieties of autoimmune diseases. Recent studies reveal that interleukin-35 (IL-35), a newly identified cytokine of IL-12 family, is implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), etc. In this review, we will discuss the biological features of IL-35 and summarize recent advances in the role of IL-35 in the development and pathogenesis of autoimmune diseases; the discoveries gained from these findings might translate into future therapies for these diseases.
自身免疫性疾病包含大量以多种导致自身耐受破坏的因素为特征的病理状况。细胞因子介导的免疫在多种自身免疫性疾病的发病机制中起重要作用。最近的研究表明，白细胞介素-35（IL-35）是白细胞介素-12家族新发现的一种细胞因子，与系统性红斑狼疮（SLE）、类风湿关节炎（RA）、系统性硬化症（SSc）等自身免疫性疾病的发病机制有关。在这篇综述中，我们将讨论IL-35的生物学特性，并总结IL-35在自身免疫性疾病发展和发病机制中作用的最新进展；从这些发现中获得的成果可能会转化为这些疾病的未来治疗方法。
Zotero 插件